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Aims: The overall goal of this article is to make a scientific comment about the psycho-social 
consequences of hemophilia patients affected by human immunodeficiency virus (HIV) and/or 
hepatitis C virus (HCV) and to point out the related medicolegal issues.
Methods: This commentary takes into account some published evidences about the current 
scenario of hemophilia patients infected by HIV and/or HCV who received contaminated blood 
products in the late 1970s through 1985.
Results: Several psychological and medicolegal consequences are related with HIV and HCV 
contamination of blood products. A multidisciplinary approach is needed to treat all the dif-
ficulties experienced by these patients and to ensure good clinical decisions in medical practice.
Conclusion: The literature on the psychosocial functioning of hemophilia patients with human 
HIV and HCV infection offers a number of implications, including medicolegal issues, that 
can be discussed for guaranteeing a good level of care and safeguard of this group of patients.
Keywords: hemophilia, viral contaminated blood products, monetary compensation, medico-
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Thanks to technological advancements in the last 2 to 3 decades in the treatment of hemo-
philia, a genetic blood-clotting disorder, the life expectancy of patients has dramatically 
improved.1 This clinical improvement has been especially observed in relation to the new 
treatment for viral infections, such as HIV and hepatitis C virus (HCV).2,3 The HIV and 
HCV infections were a tragedy for people with hemophilia between 1979 and 1984 as 
a great majority of these patients were infected by iatrogenic causes because of recur-
rent intravenous infusions with infected blood, which were essential for their survival.4,5
Today, even if the clinical hallmark of this cohort of patients who are HIV+ has 
been totally modified, their health-related quality of life (HRQL) has not increased at 
a constant level, with serious psychological and socioeducational repercussions, which 
are not always analyzed in the literature.6–9 The ability of people with hemophilia to 
cope with their daily-life problems such as chronic and acute pain, stress in the family, 
and difficulties with social relationships has an effect on their response to HIV/HCV 
and an impact on their HRQL. As recent publications have shown, hemophilia patients 
with HIV often experience difficulties in their daily-life functioning, their intimate and 
close relationships, and their job and personal careers.10–12 The rate of patients with 
a lower level of schooling and the rate of unemployed patients are higher compared 
with the rate of hemophilia patients who are HIV– and with the general population.
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Methods
The overall goal of this article is to elaborate a scientific 
commentary about the psychosocial consequences hemo-
philia patients with HIV and/or HCV experience and to 
point out related medicolegal issues. First, we examined 
some published pieces of evidence on the psychological and 
educational consequences this cohort experiences. Second, 
we discussed regulatory rules introduced in Italy and other 
countries to prevent viral infections from contaminating 
blood products and to safeguard patients already transfused 
with virally infected blood products. Finally, we discussed 
potential implications for future research in health policy 
and decision making.
Results
Psychological consequences
Patients with hemophilia have to learn to cope with a variety 
of problems of daily living as a result of the disease, such as 
acute and chronic pain, recurrent bleeding, daily infusions, 
and restrictions in their social life.13 Therefore, we suppose 
that their reactions to HIV and HCV infection have been set 
against the lifelong problems associated with hemophilia. 
Hemophilia can be a painful condition. It is not infrequent 
for patients with hemophilia (whether HIV+ or HIV–) to 
abuse alcohol and prescribed drugs to relieve their pain.14 
Depression and moodiness have both been used to describe 
hemophilia patients, especially those who are HIV+ or HCV+. 
It is not clear whether these reported depression and moodi-
ness issues are related to the HIV infection stigma, or they 
may indeed be an early expression of infection of the central 
nervous system. Research results in this area are not congru-
ent and clear. Hemophilia patients who are HIV+ are known to 
present cognitive and neurological disorders, which, in turn, 
may compromise their emotional well-being.15
In addition, having a viral infection may cause feelings 
of anxiety and fear, with repercussions on the HRQL and 
general health status. Also, HIV+ and HCV+ patients visit a 
hemophilia clinic more frequently compared with those with-
out infections, and this has a great impact on their everyday 
life activities.15,16 In a pilot cohort study, Riva et al observed 
deficits in attention, short-term memory, abstraction, and 
visual recognition in adult hemophilia patients with HIV.11
Another challenge that hemophilia patients with HIV and 
HCV experience is adherence to their treatment regimen. The 
literature suggests wide variability of adherence in this group 
of patients, which may be associated with several factors, 
including demographics (age, family income, and housing 
stability, etc.), availability of social support, health beliefs, 
presence of a caregiver, and psychosocial functioning. As may 
be expected, patients with greater social support, those with 
more economic resources, and those with fewer symptoms 
of distress have generally better adherence.17 By evaluating 
the psychological perspective, an additional aspect of adher-
ence comes into focus. Beyond medical adherence, young 
adults and adults with HIV who choose to become sexually 
active must be concerned with adherence to safer sexual 
practices, both to protect themselves from reinfection with 
other strains of HIV and to protect their sexual partners from 
infection or reinfection with other strains of the virus. Asso-
ciations between perceived social support and safer sexual 
practices have been reported, but these have not been well 
investigated, especially in the adult population.18 However, 
adolescents and young adults with HIV who took a program 
to improve their adherence to safer sexual practices reported 
greater knowledge of protective health behaviors and were 
more likely to take actions to reduce risky sexual behaviors.19 
Interesting considerations may also be made with respect to 
the educational point of view. According to the literature, 
hemophilia patients experience a normal academic and social 
adaptation.20 However, data are not always homogeneous, 
especially in the cohort of HIV+ patients.
Previous studies have confirmed that one’s educational 
career may be affected by the presence of the virus, which can 
have an impact on a person’s general intellectual score. Some 
studies have proved that in this cohort of patients, IQ scores 
fell within the average range, but total reading scores were 
almost one standard deviation below the mean.21 Another 
variable that may have an impact on educational career is 
absenteeism. It has been found to  average 27 days, indicating 
that absenteeism may be a significant factor in the academic 
and social adaptation of children with hemophilia.12
Medicolegal consequences
After the AIDS epidemic in 1981, the occurrence of viral 
infections (especially HIV and HCV) in patients receiving 
blood products prompted government agencies in developed 
countries to implement regulatory and surveillance rules and 
to conduct criminal investigations to safeguard patients who 
are already infected and prevent similar cases in the future.22,23
For example, in France, some politicians were accused of 
delaying the implementation of blood safety measures and 
failing to question donors about drug use and homosexual 
experiences. Also, in France, the desire to use domestically 
obtained products led to the use of prisoners as major sources 
of blood until 1991. In Italy, in 1998, a civil court ruled that 
the Ministry of Health was responsible for the omission of 
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“its duties of prudence, diligence, impartiality, and legality” 
by not recommending viral inactivation treatment for blood 
products.24 Similar criminal investigations on government 
officials and pharmaceutical industry leaders were held in 
Germany, Switzerland, and Japan.23,25
Because of civil lawsuits, patients transfused with virally 
infected blood products received monetary compensation in 
the USA, Italy, France, Japan, Canada, and Australia. At the 
same time, great efforts were made to ensure the safety of 
blood products in developed countries, while blood safety 
remains a matter of concern in developing countries.23,26 
Angelotta et al noticed that some countries have promoted 
policy support programs for HIV patients but not for HCV 
ones: this is because immunosuppression-related circum-
stances among hemophiliac patients developed shortly after 
transfusions with infected blood products, whereas hepatic 
complications resulting from HCV, which develops after 2 or 
more decades from infection, are just now being diagnosed.25
In Italy, a patient infected with an HIV–-, HBV-, or HCV-
contaminated blood product can receive monetary compen-
sation in 2 ways: the “national solidarity” fund (according 
to law 210/1992) or the general principle of civil liability.
In February 1992, a law was promulgated (referred to as 
210/1992) to provide economic indemnity for patients per-
manently impaired by infected (HIV, HBV, and HCV) blood 
products or by compulsory vaccinations. This law introduced 
a “social security-type intervention” in which the Italian state 
itself commits to provide impaired patients with economic 
compensation under the principle of social solidarity, hence 
converting the consequences of the damage into a collective 
responsibility.27 This system implies a public responsibility 
of the Ministry of Health in the production, preparation, and 
administration of blood products. If the designated medical 
commission establishes a right to indemnity, an amount of 
money, as provided by law, is remitted to patients or their 
heirs, according to the percentage of impairment assessed. 
Similarly, in 2002, the French government introduced a 
compensation system based on national solidarity, which 
was dispensed by the National Fund for Compensation of 
Medical Accidents (ONIAM), which was merged with the 
fund for victims of HIV infection established in 1991 and 
compensated patients for the damages caused by events 
independent of any medical malpractice.
According to the general principles of civil liability and 
regardless of law 210/1992, the Italian legal system also 
provides for the possibility of obtaining monetary compensa-
tion under the principle of civil responsibility of the single 
medical practitioner, the hospital, or even the Ministry of 
Health, as an institution, in case of a criminal conduct, such 
as failing to implement controls on blood products, according 
to regulations and scientific progress.23,24
Comparing these 2 systems, on average, monetary com-
pensation granted in civil lawsuits is found more generous 
than the economic indemnity provided by law 210/1992. In 
France, as well as in Italy, compensations granted by civil 
courts are usually more substantial than those granted by 
compensation funds based on social solidarity.28
Besides law 210/1992 and civil lawsuits, regardless of the 
causes of disabilities, the Italian state provides all disabled 
citizens with social, economic, and work-related benefits ex 
lege 118/1971. In this case, economic benefits are granted to 
citizens with severe disabilities and low earnings. Previous 
studies have observed high rates of unemployment among 
patients with chronic illnesses, including HIV+ hemophilia 
patients.11,29 In Italy, in case of severe disability or poor health 
state, a worker can be declared incapable of rendering work 
or capable of rendering work with limitations. Also, permits 
to attend medical examinations and therapies are granted to 
disabled workers. In any case, the Italian Constitution forbids 
discrimination based on health status.
Future prospects and conclusion
The cohort of hemophiliac patients infected with HIV or HCV 
through blood transfusions could be an interesting population 
to evaluate the potential source of monetary compensation 
(either by civil courts or by national solidarity) and its amount. 
Further studies should also aim to evaluate whether the source 
and the amount of monetary compensation can be related to 
different rates of unemployment or different levels of school-
ing. Since the HIV epidemic in hemophilia-transfused patients 
broke out in the 1980s and 1990s, and since hemophiliac 
patients generally need transfusions during childhood, infected 
patients during those years would now have grown into adults, 
and investigation on monetary compensations could be indi-
rectly useful to retrospectively evaluate the effectiveness of 
“national solidarity” and social safeguard.
The literature on the psychosocial functioning of hemo-
philia patients with HIV and HCV infection offers a number 
of implications, including medicolegal issues, that can be 
discussed to guarantee a good level of care and protect this 
group of patients.
Of course, multidisciplinary communication must be 
encouraged, and treatment teams may include behavioral spe-
cialists who can provide education and guidance on appropriate 
developmental milestones and career opportunities.30 Counsel-
ing should be considered in light of the ecosystem in which the 
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patient lives, for example, the degree of social support received 
by the family, the coping strategies employed by the patient, 
and the number and severity of negative life events experienced 
by the patient.31 This may hold particular relevance for clinical 
work with children and families affected by HIV. To the extent 
that HIV-related stressors are controllable (e.g., adherence), 
active or problem-focused strategies should be encouraged.
Beyond that, complete counseling should also include 
information about social, work-related, and potentially eco-
nomic benefits, as provided by laws, to disabled and impaired 
patients. Information should be as thorough as possible. 
Moreover, as is well known, transfusion medicine deals 
with ethical and deontological issues with regard to clinical 
appropriateness, information and consent to or refusal of 
transfusion, safety of underage donors, and development of 
institutional programs of blood management.32
In certain cases, medicolegal experts could provide infor-
mation and professional support with regard to these issues, 
including “national solidarity” funds or compensation under 
the criminal law system.33,34
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